Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Advanced
Wish Lists Wish Lists
Wish Lists Wish Lists
Wish Lists
Cart Cart
Cart Cart
Cart
Sign in
Sign in
Contact us
Advanced
Homepage > Company > Media > Pharma News

Pharma News

Diagnostic marker found for deadly brain disease marked by dementia, movement problems. Discovery could accelerate progress toward therapies for primary tauopathies
Diagnostic marker found for deadly brain disease marked by dementia, movement problems. Discovery could accelerate progress toward therapies for primary tauopathies

Zooming in on a single disease and studying it intensely is often the most productive route to finding treatments.

J&J builds case for antidepressant Spravato with head-to-head trial
J&J builds case for antidepressant Spravato with head-to-head trial
Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in the market, and it is looking to new clinical results to accele...
FDA Approves New Dosing Schedule for Jazz Pharmaceuticals’ Rylaze
FDA Approves New Dosing Schedule for Jazz Pharmaceuticals’ Rylaze
The FDA has approved Jazz Pharmaceuticals’ supplemental Biologics License Application (sBLA) for an additional dosing schedule for Rylaze (asparaginase erwinia chrysanthemi recombinant) to treat...
FDA Accepts New Data on Apellis’ New Drug Application
FDA Accepts New Data on Apellis’ New Drug Application
The FDA has accepted Apellis Pharmaceuticals’ major amendment to its new drug application (NDA) for pegcetacoplan for the treatment of patients with geographic atrophy secondary to age-related m...
Nona and Dragonfly enter HCAb-based drug discovery partnership
Nona and Dragonfly enter HCAb-based drug discovery partnership

Nona will offer access to its technologies and antibody generation services to Dragonfly for the targets chosen by the latter.

FDA Grants Breakthrough Therapy Status to Iveric Bio’s Zimura for AMD
FDA Grants Breakthrough Therapy Status to Iveric Bio’s Zimura for AMD
The FDA has granted Breakthrough Therapy status for Iveric Bio’s Zimura (avacincaptad pegol)  for geographic atrophy secondary to age-related macular degeneration (AMD) which leads to progre...
Merck bulks up in haematology, buying Imago for $1.35bn
Merck bulks up in haematology, buying Imago for $1.35bn
While its fabled takeover of Seagen is yet to materialise, Merck & Co has continued to bolster its pipeline with smaller deals – with its latest a $1.35 billion agreement to buy Imago BioScie...
Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation
Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation
ACU193, an antibody developed based on its selectivity for soluble amyloid-ß oligomers, is currently being assessed in a phase 1 trial, with a potential phase 2/3 trial in the near future. ...
Regeneron, CytomX announce bispecific therapeutics for cancer collab
Regeneron, CytomX announce bispecific therapeutics for cancer collab
Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the treatmen...
FDA Approves Second Interchangeable Insulin Product, Rezvoglar (insulin glargine-aglr)
FDA Approves Second Interchangeable Insulin Product, Rezvoglar (insulin glargine-aglr)
The U.S. Food and Drug Administration approves the second interchangeable biosimilar insulin product to Lantus (insulin glargine), Eli Lilly’s Rezvoglar (insulin glargine-aglr).   ...
Tzield drug that can delay onset of type 1 diabetes has a pricetag close to $200,000
Tzield drug that can delay onset of type 1 diabetes has a pricetag close to $200,000
The FDA has approved Provention Bio’s Biologics License Application (BLA) for Tzield (teplizumab-mzwv) to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years a...
Camber Pharmaceuticals Launches Generic Lamictal XR
Camber Pharmaceuticals Launches Generic Lamictal XR

Camber Pharmaceuticals is pleased to announce the addition of Lamotrigine ER Tablets to its current portfolio.

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Screening Compounds
Building blocks
Inhibitors and approved drugs
Natural base
Virtual space
Drug Discovery Services
AI Kinome Profile
Al/ML Data sets
Synthetic and Medicinal Chemistry
In silico drug design (CADD)
Discovery biology
ADME, DMPK
Functional ex vivo and in vivo models
Safety and Toxicology
Company
News & Media
Contact us
Trends in discovery compounds

We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.

Accept